Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Department of Economics, Universidad de Buenos Aires, Buenos Aires, Argentina.
Appl Health Econ Health Policy. 2023 Jul;21(4):637-650. doi: 10.1007/s40258-023-00800-0. Epub 2023 Apr 16.
To estimate the budget impact of the potential coverage of FreeStyle Libre Flash Continuous Glucose Monitoring System (FSL) for glycemia monitoring in all type 1 diabetes mellitus (T1DM) patients and in those with type 2 diabetes mellitus (T2DM) with multiple daily insulin injections, from the social security and the private third-party payer's perspective in Argentina.
A budget impact model was developed to estimate the cost difference between the self-monitoring of blood glucose (standard of care) and FSL over 5 years. Input parameters were retrieved from local literature complemented by expert opinion. Health care costs were estimated by a micro-costing approach and reported in USD as of April 2022 (1 USD = 113.34 Argentine pesos). One-way sensitivity and scenario analyses were conducted.
From a social security third-party payer perspective, the incorporation of FSL was associated with net savings per member per month (PMPM) of $0.026 (Year 1) to $0.097 (Year 5) and net savings PMPM of $0.002 (Year 1) to $0.008 (Year 5) for T1DM and T2DM patients, respectively. Similar findings are reported from the private third-party payer perspective. The budget impact results were more sensitive to the acquisition costs of the FSL and test strips.
The potential coverage of FSL in patients with T1DM and T2DM with multiple daily insulin injections could be associated with small financial savings considering current technology acquisition costs (FSL and test strips) for social security and the private sector third-party payers in Argentina.
从社会保障和私人第三方支付者的角度，估算在阿根廷将 FreeStyle Libre Flash 连续血糖监测系统（FSL）用于所有 1 型糖尿病（T1DM）患者和接受多次胰岛素注射的 2 型糖尿病（T2DM）患者血糖监测的潜在覆盖范围的预算影响。
开发了一个预算影响模型，以估算在 5 年内，与自我血糖监测（标准护理）相比，FSL 的成本差异。通过微观成本法估算医疗保健费用，并以 2022 年 4 月的美元（1 美元=113.34 阿根廷比索）计价。进行了单因素敏感性分析和情景分析。
从社会保障第三方支付者的角度来看，引入 FSL 与每位成员每月的净节省额（PMPM）相关，T1DM 患者为 0.026 美元（第 1 年）至 0.097 美元（第 5 年），T2DM 患者为 0.002 美元（第 1 年）至 0.008 美元（第 5 年）。从私人第三方支付者的角度来看，也有类似的发现。预算影响结果对 FSL 和测试条的购置成本更为敏感。
考虑到目前在阿根廷的社会保障和私人部门第三方支付者的 FSL 和测试条的技术获取成本，在 T1DM 和接受多次胰岛素注射的 T2DM 患者中，FSL 的潜在覆盖范围可能会带来少量的财务节省。
